The aim of this proposal is to identify immune biomarkers, genetic risk, and the clinical consequences of low count monoclonal B-cell lymphocytosis (LC MBL), a common premalignant condition affecting up to 17% of European adults age\>40. LC MBL is a precursor to chronic lymphocytic leukemia (CLL), characterized by a circulating population of clonal B-cells. It is relatively understudied, despite emerging evidence of clinical consequences such as increased risk for life-threatening infections and lymphoid malignancies. Studies reported that male sex, age, family history of CLL, and CLL-susceptibility genetic loci were associated with LC MBL risk. These findings were reported in European ancestry individuals and have not been generalized to other thnicities. This study will provide this missing knowledge using a unique multi-ethnic Israeli population of Jews and Arabs that have one of the highest and lowest age-standardized incidence rates of CLL in the world, respectively, and characterized with different genetic backgrounds.
Individuals over the age pf 40
Individuals with lymphoproliferative disorder
Jewish and Arab individuals over the age of 40 attending to the Clalit HMO clinics in the North of Israel for regular blood tests
Cohort
Prospective
Not listed
Assess the relationship between LC MBL and life-threatening infections, hematologic malignancies, and solid tumors among Jews and Arabs in Israel
Blood samples will be screened for MBL using flow cytometry, while data on the various outcomes will be collected from electronic medical records from Clalit Health Services.
Assess the relationship between LC MBL and cardiovascular diseases, autoimmune conditions, and Alzheimer among Jews and Arabs in Israel
Blood samples will be screened for MBL using flow cytometry, while data on the various outcomes will be collected from electronic medical records from Clalit Health Services.
Identify germline genetic factors that are associated with LC MBL risk among Jews and Arabs in Israel
DNA will be extracted from the blood sample and sequenced.
Evaluate the prevalence of LC MBL by Jews and Arabs and by sex in Israel.
Blood samples will be screened for MBL using flow cytometry, ethnicity and sex will be determined using a demographic questionnaire
Assess the relationship between LC MBL and other clinical conditions
Other clinical conditions will be determined from electronic medical records from Clalit Health Services
Click on the lead sponsor to view all of their trials.
University of Haifa
Lead sponsor
Clalit Health Services, Haifa and West Galilee
Collaborator
Bnai Zion Medical Center
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
